| Gene symbol | VEGFA | Synonyms | L-VEGF, MVCD1, VEGF, VPF | Type of gene | protein-coding |
| Chromosome | 6 | Map location | 6p21.1 | dbXrefs | |
| Gene perturbation-related omics dataset | PerturbAtlas | PertOrg | ||||
| Description | vascular endothelial growth factor A | ||||
| GTO ID | GTC1232 |
| Trial ID | NCT00134667 |
| Disease | Age-Related Macular Degeneration |
| Altered gene | VEGFA |
| Therapeutic/Target gene | Target gene |
| Therapy | Aptamer |
| Treatment | Macugen|pegaptanib|EYE001 |
| Co-treatment | Photodynamic Therapy (PDT) with Visudyne (verteporfin) |
| Phase | Phase4 |
| Recruitment status | Terminated |
| Title | A Phase IIIb/IV Randomized, Double-Masked, Active Controlled, Dose-Ranging, Multi-Center Comparative Trial, in Parallel Groups, to Compare the Safety and Efficacy of Intravitreal Injections of Pegaptanib Sodium (Macugen) Given Every 6 Weeks for 102 Weeks, to Pegaptanib Sodium Plus Photodynamic Therapy (PDT) With Visudyne, in Patients With Exudative Age-Related Macular Degeneration (AMD) |
| Year | 2005 |
| Country | United States |
| Company sponsor | Eyetech Pharmaceuticals |
| Other ID(s) | EOP1012 |
| Cohort 1 | |||||||
|
|||||||